Core Insights - EngineAI Robotics has launched the EngineAI T800, a full-size, high-performance humanoid robot, which has entered mass production, marking a significant milestone in industrial deployment [1] - The company has secured a total of 1 billion yuan in cumulative Pre-A++ and Series A1 funding, completing both Series A1+ and Series A2 financing rounds to enhance core R&D and product upgrades [1][3] Funding and Investment - The Series A2 funding round features a strong capital structure with top-tier capital partnering with state-owned entities, showcasing a multi-capital support system [4] - Huangpu River Capital (HPR) led the Series A2 round, demonstrating confidence in EngineAI's self-developed technology and market implementation [6] - Established investors have increased their stakes, and six new institutional partners have joined, creating a diversified capital support ecosystem for EngineAI [7] Product Development and Innovation - The T800 represents a breakthrough in humanoid robotics, achieving superior physical performance and addressing industry challenges such as low task success rates [10][11] - EngineAI has developed a comprehensive product spectrum, including four configuration variants of the T800 tailored for various applications [12] - The company has established its own production line in Shenzhen and plans to build a global manufacturing hub in Zhengzhou to support mass production [13] Future Outlook - EngineAI aims to deepen technological iteration and build an industrial ecosystem, focusing on system design, motion control algorithms, and embodied intelligence [14] - The company is committed to enhancing task execution efficiency and ensuring high success rates through a complete technical chain [15] - EngineAI seeks to collaborate with industry partners to advance humanoid robotics technology and integrate smart technology into everyday life [17]

Core Insights - Kraig Biocraft Laboratories, Inc. has been granted usage rights to government-owned mulberry gardens, which will support its spider silk production expansion [1][2][5] - The mulberry gardens will provide essential feedstock for the production of recombinant spider silk, aimed at high-performance textiles and luxury fashion markets [2][4] - This strategic move enhances the company's supply chain control and production capacity, aligning with its long-term commercialization goals [3][5] Company Developments - The land-use rights were granted by a key government agency, reflecting a collaborative relationship that is crucial for the company's growth [2][5] - Kraig Labs is finalizing materials for a pilot development program with a leading performance sports apparel brand, indicating strong commercial interest in its products [4] - The integration of the mulberry gardens into the production pipeline will involve additional staffing and operational resources to support production increases [5]

Core Insights - Orchestra BioMed is collaborating with Medtronic to develop and commercialize AVIM Therapy for treating uncontrolled hypertension in patients indicated for a pacemaker [1][4] - The company presented at the 2025 Innovation in Cardiology Intervention meeting, focusing on AVIM Therapy and Virtue Sirolimus AngioInfusion™ Balloon [1][2] Company Overview - Orchestra BioMed is a biomedical innovation company that accelerates high-impact technologies through strategic collaborations with leading medical device companies [4] - The two flagship products, AVIM Therapy and Virtue SAB, represent multi-billion-dollar annual global market opportunities [4] AVIM Therapy - AVIM Therapy is designed to lower blood pressure significantly and persistently in patients with hypertension who are also indicated for a pacemaker [5][6] - Pilot studies showed net reductions of 8.1 mmHg in ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months compared to control patients [6] - The BACKBEAT global pivotal study is currently evaluating the safety and efficacy of AVIM Therapy in patients with systolic blood pressure above target despite anti-hypertensive medication [6] Virtue Sirolimus AngioInfusion™ Balloon (Virtue SAB) - Virtue SAB is a novel drug delivery system designed for coronary artery disease treatment, utilizing a non-coated microporous AngioInfusion™ Balloon [3][7] - The system delivers a proprietary extended-release formulation of sirolimus, achieving sustained tissue levels above the therapeutic concentration required to inhibit restenosis [7] - Virtue SAB has shown positive three-year clinical data in coronary in-stent restenosis and has received Breakthrough Device Designation from the FDA for multiple indications [7]

Core Insights - Kamada Ltd. announced the discontinuation of the Phase 3 InnovAATe trial for Inhaled AAT due to an interim futility analysis indicating low likelihood of achieving statistically significant benefits in lung function [1][5] - The company remains committed to supporting the Alpha-1 Antitrypsin Deficiency (AATD) community through its existing product GLASSIA and is focused on future growth prospects despite the trial's outcome [2][5] Financial Guidance - Kamada reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million [2][5] - The company projects double-digit growth in revenues and profitability for 2026, with detailed guidance to be provided in January 2026 [2][5] Business Strategy - Kamada's growth strategy includes organic growth from its commercial activities, business development opportunities, and expansion of plasma collection operations [4][6] - The company currently operates three plasma collection centers in the U.S. and aims to enhance its marketed products portfolio through potential collaborations and acquisitions [4][6] Company Overview - Kamada is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [4][6] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of its outstanding shares [6]

SHENZHEN, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that EngageLab, its leading omni-channel customer engagement platform, officially launches its new AI-driven customer service platform - LiveDesk. Built on the core principle of “AI Agent x Human Agent” deep collaboration, the platform is dedicated to helping enterprises efficiently addr ...

Core Viewpoint - OR Royalties Inc. has announced a normal course issuer bid (NCIB Program) to repurchase up to 9,399,294 common shares, representing approximately 5% of the issued shares, with a total budget of C$28.0 million for 2025 [1][6][7]. Summary by Sections NCIB Program Details - The NCIB Program is approved by the Toronto Stock Exchange (TSX) and allows the company to acquire shares through open market transactions or other permitted means [1][2]. - Repurchases may start on December 12, 2025, and will end on December 11, 2026, with daily purchases limited to 107,496 shares [3]. - The purchase price for shares will be the market price at the time of acquisition, plus any applicable brokerage fees [4]. Rationale for Share Repurchase - The Board of Directors believes that the market price does not reflect the underlying value of the company, and repurchasing shares will benefit remaining shareholders by increasing their proportional interest [5]. Historical Context - Under the previous NCIB Program, which ran from December 12, 2024, to December 11, 2025, the company repurchased 228,183 shares at an average price of approximately C$45.83, totaling C$28.0 million in 2025 [7].

Core Insights - EUDA Health Holdings Limited is launching an integrated digital health and rewards platform utilizing a utility cryptocurrency called QB, set to launch in January 2026 [1][2] - The QB cryptocurrency will facilitate payments, rewards, and access to EUDA's healthcare products and services, enhancing the connection between healthcare and digital finance [2][3] - This initiative aims to transform healthcare engagement into tangible economic and health benefits, promoting a unified ecosystem that combines wellness products and digital assets [3][4] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [4] - The company aims to lead the transformation from reactive medical treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [4]

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3, IL-31, IgE, and in core Type 2 inflammation and ...

Strong sulphur and third-party processing revenue support robust cash flow and debt reduction targets for 2026; successful execution of strategic plan delivers exceptional shareholder returnsNot For Distribution to United States News Wire Services or Dissemination in United States CALGARY, Alberta, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cavvy Energy Ltd. (“Cavvy” or the “Company”) (TSX:CVVY) is pleased to release 2026 guidance, highlighted by accelerated debt reduction targeting $50 million and an increase in ne ...

Represents first contract under Approved Supplier Status with Global Aerospace LeaderMONTREAL, Dec. 08, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of a half-tonne contract with a Global Aerospace Leader for the supply of titanium metal powder produced by PyroGenesis’ NexGen™ plas ...